PI
IGMS

Pennant Investors’s IGM Biosciences IGMS Stock Holding History

Pennant Investors’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-64,900
Closed -$446K – 32
2024
Q2 		$446K Hold
64,900
– – 0.12% 25
2024
Q1 		$626K Hold
64,900
– – 0.16% 19
2023
Q4 		$539K Buy
+64,900
New +$377K 0.12% 18

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pennant Investors's IGMS Position: Q3 2024 in Review

Pennant Investors sold out of IGM Biosciences (IGMS) in Q3 2024, closing a stake of 64,900 shares — an estimated $446K sold.

Pennant Investors first reported a position in IGMS in Q4 2023 and held it in 3 quarters. The position peaked at $626K in Q1 2024. 72 funds tracked by Wall St. Rank hold IGMS as of Q3 2024.

  • Pennant Investors reported no remaining IGM Biosciences position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 64,900 IGM Biosciences shares in Q3 2024, an estimated $446K.
  • Pennant Investors first reported a position in IGM Biosciences in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's IGM Biosciences position peaked at $626K in Q1 2024.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.